Stocks · Healthcare · Biotechnology
Aclaris Therapeutics, Inc. ACRS
$4.39 -0.45% Close, Oct 2, 2026 · NASDAQ · Market cap $613.1M
High risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -1050.2% from -873.4% a year earlier.
- The diluted share count rose 16.4% in a year.
- Over the past year the stock returned +134.8%, ahead of the S&P 500 by 119.7 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 12%
- Revenue growth, 3-year CAGRBottom 4%
- Revenue growth accelerationTop 29%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 22%
- Gross marginTop 13%
- Operating marginBottom 11%
- Accruals (lower is better)Top 45%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 41%
- Free-cash-flow yieldBottom 37%
- EBITDA / enterprise valueBottom 36%
- Sales / enterprise valueBottom 10%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 6%
- 6-month returnBottom 47%
- 1-year return vs S&P 500Top 9%
- Distance from 52-week highBottom 48%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 50%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 43%
- Upside to consensus price targetTop 28%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 32%
- Maximum drawdown, 3 yearsBottom 14%
- Beta vs S&P 500 (lower is better)Bottom 27%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -52.9% | -51.0% | ↑ |
| Gross margin | 16.2% | 95.6% | ↑ |
| Operating margin | -873.4% | -1050.2% | ↓ |
| FCF margin | -278.1% | -756.5% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -51.0% | -52.9% | ↑ | Bottom 12% |
| Gross margin | 95.6% | 16.2% | ↑ | Top 13% |
| Operating margin | -1050.2% | -873.4% | ↓ | Bottom 11% |
| Net margin | -921.5% | -802.0% | ↓ | — |
| Free-cash-flow margin | -756.5% | -278.1% | ↓ | — |
| Return on invested capital | -57.0% | — | Bottom 22% | |
| Revenue growth, 3-year CAGR | -35.9% | — | Bottom 4% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -7.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 141.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +3151.6 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -9.41%
- Shareholder yield
- -9.41%
- Share count change, 1 year
- +16.4%
- Share count change, 3-year CAGR
- +26.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +3.4%
- Average 2-day reaction, last 8
- -0.9%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $10.60
- Target vs current price
- +141.5%
- Analysts with a rating
- 16
- Share rating Buy or Strong Buy
- 81%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +6.3% | -4.2% | -8.2% | -2.8% | — |
| May 7, 2026 | +6.3% | +1.7% | +6.5% | -1.5% | +15.7% |
| Feb 26, 2026 | -6.7% | -5.4% | -6.3% | +8.5% | +37.2% |
| Nov 6, 2025 | +7.7% | +0.4% | +6.6% | +33.2% | +53.5% |
| Aug 7, 2025 | +0.0% | +1.3% | +9.7% | +33.5% | +60.6% |
| May 8, 2025 | +29.4% | +4.8% | -5.6% | +24.8% | +24.8% |
| Feb 27, 2025 | -215.6% | -7.1% | -11.9% | -22.9% | -40.0% |
| Nov 6, 2024 | -37.5% | +1.8% | +15.3% | +69.4% | +13.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.15 | -$0.16 | +6.3% | $1.6M |
| May 7, 2026 | -$0.15 | -$0.16 | +6.3% | $2.0M |
| Feb 26, 2026 | -$0.16 | -$0.15 | -6.7% | $1.3M |
| Nov 6, 2025 | -$0.12 | -$0.13 | +7.7% | $3.3M |
| Aug 7, 2025 | -$0.13 | -$0.13 | +0.0% | $1.8M |
| May 8, 2025 | -$0.12 | -$0.17 | +29.4% | $1.5M |
| Feb 27, 2025 | -$1.01 | -$0.32 | -215.6% | $9.2M |
| Nov 6, 2024 | -$0.11 | -$0.08 | -37.5% | $4.3M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 72.27× | — | — | Bottom 10% |
| Free-cash-flow yield | -10.14% | — | — | Bottom 37% |
| Earnings yield | -13.21% | — | — | Bottom 41% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -0.4%
- 200-day average slope (20 days)
- +6.1%
- Distance from 50-day average
- -23.1%
- Distance from 200-day average
- -1.3%
- RSI (14)
- 30.8
- Relative volume
- 2.10×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 67.0%
- Volatility vs own 5-year history
- 52th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.64
- Correlation with S&P 500
- 0.23
- Current drawdown from 1-year high
- -32.9%
- Maximum drawdown, 3 years
- -90.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 7, 2021 | Nov 13, 2023 | -97.8% | 656 days | Not yet recovered |
| Oct 9, 2020 | Nov 19, 2020 | -34.9% | 29 days | 18 days (Dec 16, 2020) |
| Dec 24, 2020 | Jan 13, 2021 | -23.0% | 12 days | 3 days (Jan 19, 2021) |
| Mar 22, 2021 | Mar 24, 2021 | -18.8% | 2 days | 7 days (Apr 5, 2021) |
| Feb 12, 2021 | Feb 24, 2021 | -14.6% | 7 days | 11 days (Mar 11, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $613.1M
- EPS, diluted (TTM)
- -$0.58
- Revenue (TTM)
- $8.2M
- 52-week range
- $1.74 – $6.60
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M |
| Gross profit | $2.0M | $17.8M | $13.2M | $15.9M | $5.7M |
| Operating income | -$89.7M | -$89.9M | -$97.4M | -$141.9M | -$76.4M |
| Net income | -$90.9M | -$86.9M | -$88.5M | -$132.1M | -$64.9M |
| EPS (diluted) | -$1.60 | -$1.33 | -$1.27 | -$1.71 | -$0.53 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3M | $9.2M | $1.5M | $1.8M | $3.3M | $1.3M | $2.0M | $1.6M |
| Net income | -$7.6M | -$96.6M | -$15.1M | -$15.4M | -$14.6M | -$19.8M | -$19.8M | -$21.5M |
| EPS (diluted) | -$0.11 | -$1.01 | -$0.12 | -$0.13 | -$0.12 | -$0.16 | -$0.15 | -$0.15 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$52.1M | -$67.6M | -$78.3M | -$20.1M | -$47.1M |
| Capital expenditure | -$308,000 | -$605,000 | -$1.3M | -$121,000 | -$111,000 |
| Free cash flow | -$52.4M | -$68.2M | -$79.6M | -$20.2M | -$47.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $238.2M | $72.7M | $26.7M | $74.9M | -$446,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $91.6M
- Total assets
- $179.7M
- Total liabilities
- $55.1M
- Total debt
- $0
- Net debt
- -$19.2M
- Shareholders’ equity
- $124.6M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 16,075,295
- Days to cover
- 6.38
- Change vs previous report
- +5.9%
FINRA short interest, settlement date Sep 15, 2026.